Carranza MJ, Escutia VY

Language: Spanish
References: 15
Page: 3-8
PDF size: 75.01 Kb.

ABSTRACT

Background: Diabetes mellitus is the fi rst cause of death in Mexico, which becomes a public health problem affecting 10% of adults older than 20 years.
Objective: To report the results of an intensive and physio-pathogenic treatment scheme applied to diabetic patients assisted in a second level hospital.
Patients and methods: Patients with diabetes diagnosis established at Metabolic Syndrome Clinic of General Hospital Dr. Miguel Silva, Morelia, Michoacan. All physicians assisted their patients following the specifi c guidelines about indication of diet, exercise and drugs (simple carbohydrate, starch and saturated fats restriction, increased intake of monounsaturated fats and soluble fi ber-rich foods and practicing of aerobic exercise).
Results: One hundred ninety-two patients with a mean age of 54.7 years were assisted, with evolution since diagnosis, in average, of 6.9 years. With the intensive treatment signifi cant decrements in fasting glycemia, postprandial glycemia, glycated hemoglobin, total cholesterol, triglycerides, LDL-C and diastolic blood pressure were registered.
Conclusions: Intensive medical assistance of diabetes, which includes lipids and blood pressure goals, besides of glucose’s, has demonstrated to reduce the cardiovascular risk.

REFERENCES

1. Causas de Mortalidad en México 2003: Estadísticas de Mortalidad, Secretaría de Salud. http://www.ssa.gob.mx.

2. Velázquez-Monroy y col. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México: Resultados fi nales de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2003;73:62- 77.

3. American Diabetes Association. Standard of Medical Care in Diabetes-2007. Diabetes Care 2007;30 suppl 1:S4-S41.

4. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Associations for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. European Heart Journal 2007;28:88-136.

5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fi nal report. Circulation 2002;106:3143-421.

6. Chobanian A, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.

7. Grupo Mexicano de Hipertensión. Actualización del Consenso Nacional de Hipertensión Arterial. Med Int Mex 2006;22:44- 78.

8. Gaede P, Vedel P, Laersen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.

9. Hatorpe V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002;41:471-83.

10. McLeod JF. Clinical pharmacokinetics of neteglinide. Clin Pharmacokinet 2004;43:97-120.

11. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelveweek Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes. Horm Metab Res 2006;38:423-28.

12. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin Noth Am 1997;26:511-21.

13. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin an update. Ann Intern Med 2002;137:25-33.

14. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-mont randomized placebo-controlled dose-response study. The pioglitazona 001 Study Group. Diabetes Care 2000;23:1605-11.

15. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone Clinical Trials Study Group. The rosiglitazone clinical trials study group: rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-88.